...
首页> 外文期刊>European Journal of Pharmacology: An International Journal >Metabotropic glutamate 7 receptor agonist AMN082 inhibits glutamate release in rat cerebral cortex nerve terminal
【24h】

Metabotropic glutamate 7 receptor agonist AMN082 inhibits glutamate release in rat cerebral cortex nerve terminal

机译:代谢谷氨酸7受体激动剂AMN082抑制大鼠脑皮层神经末端的谷氨酸释放

获取原文
获取原文并翻译 | 示例
           

摘要

AMN082 is a selective metabotropic glutamate mGlu(7) receptor agonist reported to exhibit antidepressant activity. Considering that excessive glutamate release is involved in the pathogenesis of depression, the effect of N, N'-dibenzyhydryl-ethane-1,2-diamine dihydrochloride (AMN082) on glutamate release in rat cerebrocortical nerve terminals and the possible underlying mechanism were investigated. In this study, we observed here that AMN082 inhibited 4-aminopyridine-evoked glutamate release and this phenomenon was blocked by the metabotropic glutamate mGlu(7) receptor antagonist MMPIP. Moreover, western blot analysis and immunocytochemistry confirmed the presence of presynaptic metabotropic glutamate mGlu(7) receptor proteins. The effect of AMN082 on the 4-aminopyridine-evoked release of glutamate was prevented by chelating the extracellular Ca2+ ions and the vesicular transporter inhibitor; however, the effect of AMN082 was unaffected by the glutamate transporter inhibitor. AMN082 reduced the elevation of 4-aminopyridine-evoked intrasynaptosomal Ca2+ concentration, but did not alter the synaptosomal membrane potential. In the presence of the Ca(v)2.2 (N-type) and Ca(v)2.1 (P/Q-type) channel blocker, the adenylate cyclase inhibitor, and the protein kinase A inhibitor, the action of AMN082 on the 4-aminopyridine-evoked glutamate release was markedly reduced. These results suggest that the activation of the metabotropic glutamate mGlu(7) receptors by AMN082 reduces adenylate cyclase/protein kinase A activation, which subsequently reduces the entry of Ca2+ through voltage-dependent Ca2+ channels and decreases evoked glutamate release. Additionally, fluoxetine, a clinically effective antidepressant, completely occluded the inhibitory effect of AMN082 on glutamate release, thus indicating the existence of a common intracellular mechanism for these two compounds to inhibit glutamate release from the cerebrocortical nerve terminals.
机译:AMN082是选择性代谢型谷氨酸组mGlu(7)受体激动剂报道显示出抗抑郁活性。考虑到过度的谷氨酸释放参与抑郁症的发病机制,N,N'-dibenzyhydryl - 乙烷-1,2-二胺二盐酸盐的对谷氨酸的释放在大鼠大脑皮层神经末梢的效果(AMN082)和可能的机制进行了研究。在这项研究中,我们在这里指出,AMN082抑制4-氨基吡啶诱发谷氨酸释放,这现象被阻止通过代谢型谷氨酸组mGlu(7)受体拮抗剂MMPIP。此外,蛋白质印迹分析和免疫细胞化学证实突触前代谢型谷氨酸组mGlu(7)受体蛋白的存在。被阻止通过螯合细胞外Ca 2+离子和囊泡转运蛋白抑制剂AMN082对谷氨酸的4-氨基吡啶诱发释放的影响;然而,AMN082的作用是通过谷氨酸盐转运蛋白抑制剂的影响。 AMN082降低4-氨基吡啶诱发突触体内钙离子浓度升高,但并没有改变突触膜电位。在存在钙(V)2.2(N型)和Ca(V)2.1(P / Q型)通道阻断剂,所述腺苷酸环化酶抑制剂,蛋白激酶A抑制剂,AMN082对4的作用氨基吡啶诱发谷氨酸释放显着减少。这些结果表明,代谢型谷氨酸组mGlu的激活(7)受体由AMN082减少腺苷酸环化酶/蛋白激酶A的激活,其随后降低了钙离子通过电位依赖性钙离子通道的入口和减小诱发谷氨酸释放。此外,氟西汀,临床有效的抗抑郁药,完全闭塞上谷氨酸释放AMN082的抑制效果,因此表明用于从大脑皮层神经末梢这两种化合物以抑制谷氨酸释放的共同的胞内机制的存在。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号